A volunteer receives a dose of CureVac vaccine or a placebo throughout a research by the German biotech agency CureVac as a part of a testing for a brand new vaccine towards the coronavirus illness (COVID-19), in Brussels, Belgium March 2, 2021. REUTERS/Yves Herman
BERLIN, Oct 12 (Reuters) – CureVac (5CV.DE) will withdraw its first-generation COVID-19 vaccine candidate and concentrate on collaborating with GSK (GSK.L) to develop second-generation mRNA vaccine expertise as a substitute, the Germany-based biotechnology firm stated on Tuesday.
The corporate stated it’ll withdraw its first-generation vaccine candidate CVnCoV, which failed late-stage trials with 47% accuracy in June, because of a possible overlap with approval timelines for a second-generation candidate. read more
The earliest potential approval of CVnCoV would have come within the second quarter of 2022 when the candidates from the second-generation vaccine program are anticipated to progress to late-stage scientific improvement by that point, CureVac stated.
Reporting by Zuzanna Szymanska
Modifying by Riham Alkousaa
Our Requirements: The Thomson Reuters Trust Principles.
0 Comments